Adagene (ADAG) to Release Quarterly Earnings on Thursday

Adagene (NASDAQ:ADAG) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Adagene to post earnings of ($0.33) per share for the quarter.

Adagene Price Performance

ADAG opened at $1.77 on Tuesday. The company’s 50 day simple moving average is $1.88 and its 200-day simple moving average is $2.19. Adagene has a one year low of $1.64 and a one year high of $3.58.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. HC Wainwright boosted their target price on Adagene from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Morgan Stanley cut shares of Adagene from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 31st.

About Adagene

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.